The management of advanced nodal disease in patients treated with chemoradiotherapy has been a controversial topic for many years. New data have recently been reported, including the results of a multicentre randomized trial making this review timely.
INTRODUCTION
The management of advanced nodal (N2-N3) disease in patients with head neck cancer treated with primary chemoradiotherapy (CRT) continues to vary widely between institutions and countries. Although many in the United States adopt imageguided, response-based strategies, a significant proportion in other countries still practise planned neck dissection. For example, up to 48% of patients with oropharyngeal cancer in the United Kingdom were found to have neck dissection as their first treatment in a recent national audit [1] . In France, 35% of head neck clinicians surveyed reported that they commonly or routinely perform neck dissection before CRT [2 & ]. These variations in practice are mainly because of contradicting evidence and the lack of randomized comparative studies. This article reviews the most recent data in the field.
LITERATURE SUPPORTING PLANNED NECK DISSECTION
Previous retrospective studies showed that 40% of neck dissections after CRT contained persistent disease on histopathological examination [3] . There was also level 3 evidence from retrospective studies demonstrating a significant survival advantage in favour of planned neck dissection, compared with CRT alone [4, 5] . As a result, traditionally, these patients have been treated with a 'planned' neck dissection, either before or after CRT, despite the risk of significant morbidity and even mortality [6] .
LITERATURE SUPPORTING IMAGE-GUIDED SURVEILLANCE
As the quality of cross-sectional imaging improved over the past 2 decades, studies consistently reported low rates of recurrence following imageguided surveillance. For example, Thariat et al. [2 & ] reported rates of recurrence of 4% in the 30% of patients showing complete response on computer tomography (CT) scans. However, those patients who showed partial response or equivocal complete response on CT scanning had high recurrence rates of 37 and 32% respectively if they did not have a neck dissection. Such data have stimulated the increasing adoption of response-based approaches following CRT.
EFFICACY OF [ 18 F]-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTER TOMOGRAPHY IN THIS INDICATION
The advent of PET, using [ 18 F]-fluorodeoxyglucose (FDG PET), is a form of functional imaging which identifies abnormal metabolic activity of tumour cells and specifically increased glucose metabolism in tumour cells. It potentially conferred advantages over other cross-sectional imaging modalities in identifying residual disease following CRT. More recently, combined PET-CT scanners have been developed. PET-CT localizes abnormal functional metabolic activity of tumour cells, and also shows structural abnormalities, such as nodal enlargement. There have been two notable meta-analyses assessing the diagnostic performance of FDG PET and FDG PET-CT in this indication. These have included mainly single hospital, retrospective and prospective studies. The meta-analyses demonstrated high negative predictive values of 94.5-96% with positive predictive values of approximately 50% for FDG PET and FDG PET-CT scanning follow-
. FDG PET and PET-CT scanning may therefore be able to identify even more patients with complete response following CRT, resulting in fewer neck dissections [9] .
Till recently, there was no prospective multicentre, randomized evidence. However, the PET-NECK study has recently reported [10 && ]. The study recruited 564 patients, randomized into either a planned neck dissection arm or a PET-CT active surveillance arm. PET-CT was noninferior in terms of overall survival (i.e. there was no survival detriment for not having or delaying neck dissection) and only 19% of patients had a neck dissection in the PET-CT arm, with less complications and the same overall quality of life. The active surveillance PET-CT arm was significantly more cost effective than the planned neck dissection arm.
HUMAN PAPILLOMAVIRUS DISEASE AND EQUIVOCAL POSITRON EMISSION TOMOGRAPHY-COMPUTER TOMOGRAPHY RESULTS
In our PET-NECK study, patients with equivocal responses on FDG PET-CT scanning received a neck dissection. Our definition of equivocal responses included those patients with residual masses but no FDG uptake or those patients with mild FDG uptake regardless of nodal size.
Patients who had demonstrated equivocal complete responses on CT scanning after CRT had a high nodal recurrence rate of 37%, similar to that of patients who showed partial or no response [2 & ]. Recent reports suggest human papillomavirus (HPV)þ nodal disease may take longer to reduce in size [11 & ], and therefore may present with equivocal FDG PET-CT scans (in particular with enlarged nodes on the CT scan component, but without FDG avidity) at the 12 week post-CRT assessment. Other recent reports suggest that patients who show no FDG uptake had very low recurrence rates, especially if they had HPVþ disease (93%) [9, 12] . Therefore, patients with HPVþ disease who show enlarged nodes but no FDG uptake after CRT may be considered for close surveillance with serial frequent scans. Patients with FDG uptake should continue to have a neck dissection, especially if they have HPVÀ or high risk HPVþ disease. The role of ultrasound-guided biopsies and diffusion-weighted MRI should be evaluated in this group of patients.
[ 18 F]-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTER TOMOGRAPHY VERSUS COMPUTER TOMOGRAPHY-GUIDED SURVEILLANCE
A prospective study by Moeller et al. [13] reported that the diagnostic accuracy of FDG PET-CT was only better than CT in high-risk patients who have HPVÀ disease, nonoropharyngeal primaries or who have a smoking or alcohol history. There was no benefit seen in low-risk patients who are nonsmokers with HPVþ oropharyngeal primaries. The
KEY POINTS
To date, management of advanced nodal disease in patients treated with chemoradiotherapy has been varied and controversial.
Very recent level 1 evidence shows that PET-CT-guided surveillance is more cost effective than planned neck dissection for the management of this indication.
Studies providing level 2/3 evidence suggest that CTguided surveillance may also be effective in this setting.
Cost-effectiveness analysis suggests that protocols including PET-CT are more cost effective than those that rely on CT scanning alone.
authors acknowledged that the study was limited for several reasons. First, it was performed in a highthroughput cancer institution in which the proportion of high-risk patients and radiotherapy nonresponders may be greater than in other treatment settings. Second, FDG PET-CT nodal response was assessed at a mean of 8 weeks (range 5-12 weeks) following treatment, which may not be the optimal timing for FDG PET-CT after radiotherapy [7 & ]. Finally, histopathology of post-CRT neck dissection was used as evidence of persistent disease, which overestimates tumour persistence [9,14 && ]. Indeed, other studies that compared FDG PET-CT to CT have reported much higher efficacy of FDG PET-CT compared with CT in HPVþ patients. Mak et al. [12] reported that FDG PET/PET-CT scanning at a mean time of 12 weeks (range 8-16 weeks) following treatment was significantly more accurate at predicting complete response (90%) compared with contrasted CT assessment (46%), and especially for HPVþ patients (93% vs. 50%). In one of the largest studies to date, which specifically considered FDG PET-CT response in HPVþ oropharyngeal cancer, FDG PET-CT at 12 weeks after CRT demonstrated high negative predictive value for loco-regional failure though with disappointing positive predictive value and sensitivity [15] .
Pryor et al.
[14 && ] demonstrated that surveillance strategies utilizing FDG PET-CT were more cost effective than CT-guided surveillance alone, regardless of the HPV status of the patient. Furthermore, that study showed that combined strategies using CT followed by FDG PET-CT in nonresponders were only slightly more cost effective than FDG PET-CT alone, and were very sensitive to changes in circumstances.
As yet, independent validation of CT scandriven response systems or comparison with PET-CT-driven systems in multicentre, randomized settings have not been published. Even if further studies show that FDG PET-CT is of limited value in HPVþ patients, it should perhaps be noted that in many countries, this low-risk HPVþ constitutes only a minority of patients, and FDG PET-CT would still have an important role in the majority of patients.
CONCLUSION
There now appears to be strong, level 1 evidence to support FDG PET-CT-guided surveillance for patients with advanced nodal disease treated with CRT. There is also a large body of retrospective evidence to support CT-guided surveillance. However, the available evidence favours FDG PET-CTguided policies over CT-only-guided regimens on the basis of cost effectiveness.
